Background: There is no universally accepted protocol for gross examination of pancreaticoduodenectomy specimens. Standardized protocol (SP), known as Leeds Pathology Protocol, was previously validated in pancreatic adenocarcinoma. In this study we aimed to assess usefulness of SP in a series of specimens with pancreatic, ampullary, and duodenal malignant neoplasms other than adenocarcinomas.
Materials And Methods: SP was based on multi-colour inking and serial slicing of the specimens in a plane perpendicular to the duodenal axis. SP was used in a prospective cohort of 35 neoplasms of neuroendocrine, acinar, and solid-pseudopapillary lineage (SP cohort). Surgical margin status, primary tumour stage, and lymph node yield in SP group were compared with corresponding data of a historical cohort of 19 cases examined using non-standardized protocol (NSP). Samples examined in NSP and SP cohorts were comparable in terms of basic clinical characteristics, median tumour diameter, and distribution of histopathological diagnostic categories.
Results: In SP cohort we noticed: (1) higher rate of detection of tumour tissue at surgical margins, (2) more frequent peripancreatic fat tissue invasion, (3) higher percentage of perineural invasion, (4) larger number of lymph nodes retrieved from the specimen, in comparison to NSP group. Application of SP was associated with significantly higher number of tissue blocks taken for histology.
Conclusions: SP can be successfully applied for macroscopical examination of pancreaticoduodenectomy specimens with malignant pancreatic, ampullary, and duodenal neoplasms other than adenocarcinomas. SP with proper microscopical diagnosis enables an appropriate schedule of patients with these neoplasms to adjuvant therapy and surveillance programmes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14670/HH-11-781 | DOI Listing |
Drug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), 03 BP 7021 Ouagadougou 03, Burkina Faso.
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC).
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Istanbul University, Faculty of Science, Department of Biology, Istanbul, Türkiye.
In this study, the effects of histone deacetylase inhibitor CI-994 and nanotechnological drug liposomal cisplatin LipoPlatin on Luminal A breast cancer and triple-negative breast cancer were explored using agents alone and in combination. MCF-7 and MDA-MB-231 cell lines were used. Cell viability, and cell index values obtained from xCELLigence System, MI, BrdU LI and AI were evaluated in experiments.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh-11623, Saudi Arabia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!